Regeneron

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Reuters - 4 days ago

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ +7.1% Zscaler Inc ZS.OQ +4.6% Micron Technology Inc MU.OQ +4.3% Datadog Inc DDOG.OQ +3.3% Atlassian Corp TEAM.OQ +3.1% Bottom Performers Percent Change Baker Hughes Co BKR.OQ -3.2% Marriott International Inc MAR.OQ -1.8% Diamondback Energy Inc FANG.OQ -1.4% GE Healthcare Technologies Inc GEHC.OQ -1.2% Regeneron Pharmaceuticals Inc REGN.OQ -1.2%

Reuters - 4 days ago

Odronextamab BLA For Treatment Of Relapsed/Refractory Follicular Lymphoma (Fl) And Diffuse Large B-Cell Lymphoma (Dlbcl) Accepted For FDA Priority Review

BRIEF-Odronextamab BLA For Treatment Of Relapsed/Refractory Follicular Lymphoma (Fl) And Diffuse Large B-Cell Lymphoma (Dlbcl) Accepted For FDA Priority Review Sept 29 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : ODRONEXTAMAB BLA FOR TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) AND DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) ACCEPTED F

Reuters - 6 days ago

Unity Biotechnology rises on eye disorder drug trial data

BUZZ-Unity Biotechnology rises on eye disorder drug trial data ** Shares of drug developer Unity Biotechnology UBX.O rise 3.8% to $2.47 premarket ** Company says its combination treatment with Regeneron's REGN.O aflibercept showed greater vision improvement in patients with wet age-related macular degeneration (AMD) during a mid-stage trial ** The

Reuters - 1 week ago

Regeneron Pharmaceuticals, Sanofi Say Dupixent® (Dupilumab) SBLA For Treatment Of Eosinophilic Esophagitis (EoE) Accepted For FDA Priority Review

BRIEF-Regeneron Pharmaceuticals, Sanofi Say Dupixent® (Dupilumab) SBLA For Treatment Of Eosinophilic Esophagitis (EoE) Accepted For FDA Priority Review Sept 26 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : DUPIXENT® (DUPILUMAB) SBLA FOR TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EOE) IN CHILDREN AGED 1 TO 11 ACCEPTED FOR FDA PRIORITY REVIEW TARG

Reuters - 1 week ago

Ultragenyx Launches Evkeeza In Canada To Treat A Rare Condition That Causes High Cholesterol

BRIEF-Ultragenyx Launches Evkeeza In Canada To Treat A Rare Condition That Causes High Cholesterol Sept 25 (Reuters) - Ultragenyx Pharmaceutical Inc RARE.O : ULTRAGENYX LAUNCHES EVKEEZA® (EVINACUMAB FOR INJECTION) IN CANADA FOR THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) ULTRAGENYX PHARMACEUTICAL INC - TREATMENT IS NOW AVAILAB

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

How can we help?

Live Chat Terms